These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 27324196)

  • 1. A simple model predicts UGT-mediated metabolism.
    Dang NL; Hughes TB; Krishnamurthy V; Swamidass SJ
    Bioinformatics; 2016 Oct; 32(20):3183-3189. PubMed ID: 27324196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios.
    Williams JA; Hyland R; Jones BC; Smith DA; Hurst S; Goosen TC; Peterkin V; Koup JR; Ball SE
    Drug Metab Dispos; 2004 Nov; 32(11):1201-8. PubMed ID: 15304429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extending P450 site-of-metabolism models with region-resolution data.
    Zaretzki JM; Browning MR; Hughes TB; Swamidass SJ
    Bioinformatics; 2015 Jun; 31(12):1966-73. PubMed ID: 25697821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting reactivity to drug metabolism: beyond P450s-modelling FMOs and UGTs.
    Öeren M; Walton PJ; Hunt PA; Ponting DJ; Segall MD
    J Comput Aided Mol Des; 2021 Apr; 35(4):541-555. PubMed ID: 32533369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. XenoSite server: a web-available site of metabolism prediction tool.
    Matlock MK; Hughes TB; Swamidass SJ
    Bioinformatics; 2015 Apr; 31(7):1136-7. PubMed ID: 25411327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relevance of UDP-glucuronosyltransferase polymorphisms for drug dosing: A quantitative systematic review.
    Stingl JC; Bartels H; Viviani R; Lehmann ML; Brockmöller J
    Pharmacol Ther; 2014 Jan; 141(1):92-116. PubMed ID: 24076267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Posttranscriptional regulation of uridine diphosphate glucuronosyltransferases.
    Riches Z; Collier AC
    Expert Opin Drug Metab Toxicol; 2015 Jun; 11(6):949-65. PubMed ID: 25797307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro-in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: pitfalls and promises.
    Miners JO; Knights KM; Houston JB; Mackenzie PI
    Biochem Pharmacol; 2006 May; 71(11):1531-9. PubMed ID: 16455060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucuronidation in humans. Pharmacogenetic and developmental aspects.
    de Wildt SN; Kearns GL; Leeder JS; van den Anker JN
    Clin Pharmacokinet; 1999 Jun; 36(6):439-52. PubMed ID: 10427468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data.
    Nakamori F; Naritomi Y; Hosoya K; Moriguchi H; Tetsuka K; Furukawa T; Kadono K; Yamano K; Terashita S; Teramura T
    Drug Metab Dispos; 2012 Sep; 40(9):1771-7. PubMed ID: 22685216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PBPK Modeling as a Tool for Predicting and Understanding Intestinal Metabolism of Uridine 5'-Diphospho-glucuronosyltransferase Substrates.
    Reddy MB; Bolger MB; Fraczkiewicz G; Del Frari L; Luo L; Lukacova V; Mitra A; Macwan JS; Mullin JM; Parrott N; Heikkinen AT
    Pharmaceutics; 2021 Aug; 13(9):. PubMed ID: 34575401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of cloned and expressed human liver UDP-glucuronosyltransferases for analysis of drug glucuronide formation and assessment of drug toxicity.
    Burchell B; Ebner T; Baird S; Bin Senafi S; Clarke D; Brierley C; Sutherland L
    Environ Health Perspect; 1994 Nov; 102 Suppl 9(Suppl 9):19-23. PubMed ID: 7698078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on tools for evaluation of uridine diphosphoglucuronosyltransferase polymorphisms.
    Argikar UA; Iwuchukwu OF; Nagar S
    Expert Opin Drug Metab Toxicol; 2008 Jul; 4(7):879-94. PubMed ID: 18624677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enzyme kinetics of uridine diphosphate glucuronosyltransferases (UGTs).
    Zhou J; Miners JO
    Methods Mol Biol; 2014; 1113():203-28. PubMed ID: 24523115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of UDP-sugars, UDP and Mg
    Walia G; Smith AD; Riches Z; Collier AC; Coughtrie MWH
    Xenobiotica; 2018 Sep; 48(9):882-890. PubMed ID: 28868965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In silico site of metabolism prediction for human UGT-catalyzed reactions.
    Peng J; Lu J; Shen Q; Zheng M; Luo X; Zhu W; Jiang H; Chen K
    Bioinformatics; 2014 Feb; 30(3):398-405. PubMed ID: 24273240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
    Deguchi T; Watanabe N; Kurihara A; Igeta K; Ikenaga H; Fusegawa K; Suzuki N; Murata S; Hirouchi M; Furuta Y; Iwasaki M; Okazaki O; Izumi T
    Drug Metab Dispos; 2011 May; 39(5):820-9. PubMed ID: 21282406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determination of drug glucuronidation and UDP-glucuronosyltransferase selectivity using a 96-well radiometric assay.
    Di Marco A; D'Antoni M; Attaccalite S; Carotenuto P; Laufer R
    Drug Metab Dispos; 2005 Jun; 33(6):812-9. PubMed ID: 15788539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. UDP-glucuronosyltransferases and clinical drug-drug interactions.
    Kiang TK; Ensom MH; Chang TK
    Pharmacol Ther; 2005 Apr; 106(1):97-132. PubMed ID: 15781124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comprehensive review of UDP-glucuronosyltransferase and esterases for drug development.
    Oda S; Fukami T; Yokoi T; Nakajima M
    Drug Metab Pharmacokinet; 2015 Feb; 30(1):30-51. PubMed ID: 25760529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.